Hypofractionated radiotherapy as salvage for rising prostate-specific antigen after radical prostatectomy

被引:19
|
作者
Lee, LW
McBain, CA
Swindell, R
Wylie, JP
Cowan, RA
Logue, JP [1 ]
机构
[1] Christie Hosp, Dept Clin Oncol, Manchester M20 4BX, Lancs, England
[2] Christie Hosp, Dept Med Stat, Manchester, Lancs, England
关键词
prostate cancer; radical prostatectomy; radiotherapy; salvage;
D O I
10.1016/j.clon.2004.07.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: To review the outcome of men receiving hypofractionated salvage radiotherapy for rising prostate-specific antigen (PSA) after radical prostatectomy. Materials and methods: A. retrospective analysis of 61 men referred for salvage radiotherapy for biochemical relapse after radical prostatectorny was conducted. Twenty-four men receiving hormonal therapy or with follow-up of less than 12 months were excluded. Thirty-seven men were identified, median age 64 years, median preoperative PSA 11 ng/ml (5.6-60 ng/ml), Gleason scores < 7: 70%, Gleason scores greater than or equal to 7: 30%. Twenty-seven men had positive surgical resection margins, eight had seminal-vesicle involvement and one had lymph-node involvement. Diagnosis of failure after radical prostatectomy was made on rising PSA in all cases; 19 men also had positive magnetic resonance imaging, 11 abnormal digital rectal examination and nine positive biopsy. Radiotherapy was delivered conformally to the prostatic fossa, 50-52.5 Gy in 20 fractions over 4 weeks. Date of failure after radiotherapy was defined by the American Society for Therapeutic Radiology and Oncology (ASTRO) consensus criteria or as date of commencement of hormonal therapy for rising PSA. Results: Median time front radical prostatectorny to radiotherapy was 30.6 months (8-68 months); median pre-radiotherapy PSA was 2.9 ng/ml (0.5-11.4 ng/ml). PSA response after radiotherapy was seen in 33 out of 37 (89%) patients. At median follow-up of 36 months (20-85 months), 28 out of 37 remained disease-free. Thirteen more patients have had two consecutive PSA rises. Actuarial 3-year disease-free survival is 74%. No patient has developed metastases or died of prostate cancer. Pre-radiotherapy PSA less than 2 ng/ml predicted disease-free survival (P = 0.027). No acute toxicity greater than Radiation Therapy Oncology Group (RTOG) G2 was observed. Conclusions: Salvage radiotherapy after radical prostatectomy achieved durable biochemical control in most patients. Outcome is improved if radiotherapy is delivered when PSA is less than 2 ng/ml. A policy of close monitoring after radical prostatectomy with early referral for salvage radiotherapy is advocated. (C) 2004 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:517 / 522
页数:6
相关论文
共 50 条
  • [41] PROSTATE-SPECIFIC ANTIGEN RECURRENCE AFTER RADICAL PROSTATECTOMY AND THE RISK OF DEATH
    Choueiri, Toni K.
    Chen, Ming-Hui
    D'Amico, Anthony V.
    Sun, Leon
    Robertson, Cary N.
    Walther, Philip J.
    Polascik, Thomas J.
    Albala, David M.
    Moul, Judd W.
    JOURNAL OF UROLOGY, 2009, 181 (04): : 577 - 577
  • [42] Prostate-specific antigen levels after radical prostatectomy versus brachytherapy
    Merrick, GS
    Butler, WM
    Grimm, PD
    UROLOGY, 1999, 53 (04) : 865 - 866
  • [43] Salvage radiotherapy for rising or persistent PSA after radical prostatectomy
    Song, DY
    Thompson, TL
    Ramakrishnan, V
    Harrison, R
    Bhavsar, N
    Onaodowan, O
    DeWeese, TL
    UROLOGY, 2002, 60 (02) : 281 - 287
  • [44] Salvage Radiation Therapy for Increasing Prostate-Specific Antigen After Radical Prostatectomy: Who, When, and How? Reply
    Pisansky, Thomas M.
    Stish, Bradley J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04) : 470 - +
  • [45] Prostate-specific antigen kinetics after hypofractionated stereotactic body radiotherapy for localized prostate cancer
    Kim, H. J.
    Phak, J. H.
    Kim, W. Ch.
    INTERNATIONAL JOURNAL OF RADIATION RESEARCH, 2016, 14 (04): : 297 - 303
  • [46] Hypofractionated salvage radiotherapy with simultaneous integrated boost after radical prostatectomy
    Bulychkin, P.
    Tkachev, S.
    Berdnik, A.
    Bykova, U.
    RADIOTHERAPY AND ONCOLOGY, 2014, 111 : S92 - S92
  • [47] Contemporary Imaging Technologies for Men with Rising Prostate-specific Antigen After Radical Prostatectomy and Before Early Salvage Irradiation: Where Do We Stand?
    Bossi, Alberto
    Blanchard, Pierre
    Fanti, Stefano
    EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (03): : 356 - 357
  • [48] Is there a prostate-specific antigen upper limit for radical prostatectomy?
    Gontero, Paulo
    Spahn, Martin
    Tombal, Bertrand
    Bader, Pia
    Hsu, Chao-Yu
    Marchioro, Giansilvio
    Frea, Bruno
    Van der Eeckt, Kathy
    Kneitz, Burkhard
    Frohneberg, Detlef
    Tizzani, Alessandro
    Van Poppel, Hendrik
    Joniau, Steven
    BJU INTERNATIONAL, 2011, 108 (07) : 1093 - 1100
  • [49] High-Dose Salvage Intensity-Modulated Radiotherapy With or Without Androgen Deprivation After Radical Prostatectomy for Rising or Persisting Prostate-Specific Antigen: 5-Year Results
    Ost, Piet
    Lumen, Nicolaas
    Goessaert, An-Sofie
    Fonteyne, Valerie
    De Troyer, Bart
    Jacobs, Filip
    De Meerleer, Gert
    EUROPEAN UROLOGY, 2011, 60 (04) : 842 - 849
  • [50] Salvage radiotherapy in prostate cancer patients with biochemical relapse after radical prostatectomy Prolongation of prostate-specific antigen doubling time in patients with subsequent biochemical progression
    Lohm, Gunnar
    Neumann, Konrad
    Budach, Volker
    Wiegel, Thomas
    Hoecht, Stefan
    Gollrad, Johannes
    STRAHLENTHERAPIE UND ONKOLOGIE, 2018, 194 (04) : 325 - 332